/ Not yet recruiting临床1期IIT Clinical Research of Suicide Gene Expressing Allogenic Bone Marrow Derived Mesenchymal Stem Cells(MSC11FCD) in Patients With Newly Diagnosed Glioblastoma
This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients with newly diagnosed glioblastoma. The investigational product is administered intratumorally following surgical resection. This study aims to explore whether MSC11FCD can provide a targeted, localized treatment option during the postsurgical period, potentially addressing residual tumor cells and reducing early recurrence.
/ Not yet recruitingN/AIIT Clinical Research of Suicide Gene Expressing Allogenic Bone Marrow Derived Mesenchymal Stem Cells(MSC11FCD) in Patients with Newly Diagnosed Glioblastoma
Investigator-initiated and open-labeled clinical trial for evaluation of maximum tolerented dose, safety and efficiency of MSC11FCD therapy to recurrent glioblastoma patients
100 项与 MSC11FCD 相关的专利(医药)